Specifications Manual for Joint Commission National Quality Measures (v2022A1)
Posted: 10/5/2021

Release Notes:
Release Notes
Version 2022A1

This page does not need to be edited for each new release. The list of release notes is automatically generated based on the release identified in url param.

Select Release:

Release Notes for the TJC2022A1 Manual

Measure Information Forms

SectionRationaleDescription
IMM-2 The included population list for Influenza Immunization (IMM-2) has been updated to align with the CDC’s recommendation to defer influenza vaccination for hospitalized, symptomatic COVID-19 patients.

Added updated reference for COVID-19 patients.
Included Population List

Change From:

  • Patients who have an allergy/sensitivity to the influenza vaccine, anaphylactic latex allergy or anaphylactic allergy to eggs, or for whom the vaccine is not likely to be effective because of bone marrow transplant within the past 6 months, or history of Guillian-Barre syndrome within 6 weeks after a previous influenza vaccination

Change To:

  • Patients who have an allergy/sensitivity to the influenza vaccine, anaphylactic latex allergy or anaphylactic allergy to eggs, or for whom the vaccine is not likely to be effective because of bone marrow transplant within the past 6 months, or history of Guillian-Barre syndrome within 6 weeks after a previous influenza vaccination, or symptomatic suspected or confirmed COVID-19

Added the following reference to the Selected References section:
  • Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season. MMWR Recomm Rep 2021;70(No. RR-5):1–28. DOI: http://dx.doi.org/10.15585/mmwr.rr7005a1

Data Elements

SectionRationaleDescription
Influenza Vaccination Status The measure data element Influenza Vaccination Status allowable value 4, has been updated to align with the CDC’s recommendation to defer influenza vaccination for hospitalized, symptomatic COVID-19 patients. Allowable Values:

Change From:

4   There was documentation of an allergy/sensitivity to influenza vaccine, anaphylactic latex allergy or anaphylactic allergy to eggs OR is not likely to be effective because of bone marrow transplant within the past 6 months OR history of Guillian-Barré syndrome within 6 weeks after a previous influenza vaccination.

Change To:

4   There was documentation of an allergy/sensitivity to influenza vaccine, anaphylactic latex allergy or anaphylactic allergy to eggs OR is not likely to be effective because of bone marrow transplant within the past 6 months OR history of Guillian-Barré syndrome within 6 weeks after a previous influenza vaccination OR symptomatic suspected or confirmed COVID-19.

Supplemental Materials

SectionRationaleDescription
Appendix A - Code Tables Appendix A code tables were revised to reflect the ICD-10 code updates for Fiscal Year (FY) 2022, effective for discharges October 1, 2021.

PC-06 Hemophilia codes were added to Appendix A, Table 11.31 Fetal Conditions for use per measure steward recommendation.

PC-01 Respiratory Codes were added to Appendix A, Table 11.07 Conditions Possibly Justifying Elective Delivery for use. Adding these codes will allow for patients with acute respiratory distress/failure, such as due to COVID-19 infection, to be excluded from the measure.
Multiple codes added, removed, or revised per 2022 update on these tables:
Table 10.01 Mental Disorders-HBIPS/ED
Table 10.02 Mental Disorders-ED
Table 11.30 Congenital Malformations
Table 11.35 Social Indications
Table 12.10 Organ Transplant During Current Hospitalization
Table 8.2e Surgical Intervention Procedures

PC-06:
Table 11.31 Fetal Conditions-Hemophilia Codes Added:
D66  Hereditary factor VIII deficiency
D67  Hereditary factor IX deficiency
D681 Hereditary factor XI deficiency
D682 Hereditary deficiency of other clotting factors

PC-01:
Table 11.07 Conditions Possibly Justifying Elective Delivery-Respiratory Codes Added:
J80 Acute respiratory distress syndrome  
J96.00 Acute respiratory failure, unspecified whether with hypoxia or hypercapnia  
J96.01 Acute respiratory failure with hypoxia  
J96.02 Acute respiratory failure with hypercapnia 
J96.90 Respiratory failure, unspecified, unspecified whether with hypoxia or hypercapnia 
J96.91 Respiratory failure, unspecified with hypoxia  
J96.92 Respiratory failure, unspecified with hypercapnia
R06.03 Acute Respiratory Distress Syndrome 
R09.2 Respiratory arrest

Release Notes
CPT® only copyright 2024 American Medical Association. All rights reserved.
Specifications Manual for Joint Commission National Quality Measures (v2022A1)
Discharges 01-01-22 (1Q22) through 06-30-22 (2Q22)

LICENSE FOR USE OF CURRENT PROCEDURAL TERMINOLOGY, FOURTH EDITION (“CPT®”)

CPT® only copyright 2024 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

You, your employees and agents are authorized to use CPT® only as contained in The Joint Commission performance measures solely for your own personal use in directly participating in healthcare programs administered by The Joint Commission. You acknowledge that the American Medical Association (“AMA”) holds all copyright, trademark and other rights in CPT®.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT® for resale and/or license, transferring copies of CPT® to any party not bound by this Agreement, creating any modified or derivative work of CPT®, or making any commercial use of CPT®. License to use CPT® for any use not authorized herein must be obtained through the American Medical Association, Intellectual Property Services, AMA Plaza, 330 North Wabash Avenue, Suite 39300, Chicago, Illinois 60611-5885. Applications are available at the American Medical Association Web site, www.ama- assn.org/go/cpt.

U.S. Government Rights This product includes CPT® which is commercial technical data, which was developed exclusively at private expense by the American Medical Association, 330 North Wabash Avenue, Chicago, Illinois 60611. The American Medical Association does not agree to license CPT® to the Federal Government based on the license in FAR 52.227-14 (Data Rights - General) and DFARS 252.227-7015 (Technical Data - Commercial Items) or any other license provision. The American Medical Association reserves all rights to approve any license with any Federal agency.

Disclaimer of Warranties and Liabilities. CPT® is provided “as is” without warranty of any kind, either expressed or implied, including but not limited to the implied warranties of merchantability and fitness for a particular purpose. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT®, and the (AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this product is with The Joint Commission, and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this product.

This Agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

Should the foregoing terms and conditions be acceptable to you, please indicate your agreement and acceptance by clicking below on the button labeled “accept”.

^